DS
DAWN

DRW Securities’s Day One Biopharmaceuticals DAWN Stock Holding History

DRW Securities’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,635
Closed -$108K – 1393
2025
Q4 		$108K Sell
11,635
-21,630
-65% -$181K ﹤0.01% 1061
2025
Q3 		$233K Sell
33,265
-24,539
-42% -$169K ﹤0.01% 1000
2025
Q2 		$376K Buy
+57,804
New +$398K 0.01% 629

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

DRW Securities's DAWN Position: Q1 2026 in Review

DRW Securities sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 11,635 shares — an estimated $108K sold.

DRW Securities first reported a position in DAWN in Q2 2025 and held it in 3 quarters. The position peaked at $376K in Q2 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • DRW Securities reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 11,635 Day One Biopharmaceuticals shares in Q1 2026, an estimated $108K.
  • DRW Securities first reported a position in Day One Biopharmaceuticals in Q2 2025 and held it in 3 quarters.
  • DRW Securities's Day One Biopharmaceuticals position peaked at $376K in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.